

Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.



Children's of Alabama Continuing Medical Education

International Neonatal Nephrology Symposium

***Topic(s):*** Over the last few decades, the field of critical care nephrology has flourished. Multiple international education symposiums are held each year. In 2023, the 27th AKI/CRRT in San Diego was held, as well as the 40th AKI/CRRT meeting in Vicenza, Italy which attracted hundreds of nephrologists and critical care physicians. The pediatric critical care nephrology field has begun to blossom because of this. As the field of neonatal nephrology continues to expand it is crucial for a dedicated meeting to bring together researchers, educators, and clinicians from multiple disciplines to continue the expansion. This is that meeting.

***Objectives:*** 1 Recognize the impact of fluid imbalance on clinical outcomes and develop strategies to prevent and treat fluid overload

2 Describe how different therapies to treat hypotension, patent ductus areriosus, and other neonatal conditions impact the kidney

3 Know how to monitor, diagnose, and treat hypertension in neonates and small children

4 Recognize and implement strategies aimed to prevent and treat neonatal acute kidney injury

5 Understand the current methods (and limitations of the methods) used to diagnose abnormal kidney health in neonates in the NICU and beyond

6 Understand how environmental and genetics influence normal kidney development

7 List the different research approaches that can be used to understand neonatal kidney disease

8 Appreciate the challenges that families face when receiving a prenatal diagnosis of neonatal kidney failure, the decisions they have to make, and the potential obstacles they will face in caring for their child

9 Describe the management of pulmonary and kidney disease in context of severe congenital kidney failure

10 Understand the past, present, and future of neonatal extra-corporeal therapy for children with congenital kidney disease, acute kidney injury, and hyperammonemia

11 Recognize, identify, and treat patients with multiorgan failure affecting the kidneys (heart-kidney, lung-kidney, liver-kidney, intestinal-kidney)

12 Develop strategies to perform quality assessments and quality improvements in the area of neonatal kidney disease

13 Understand how registries and existing collaboratives provide great opportunities and insights on the care of neonates at risk for kidney disease

***Date/Time:*** 9/12/2024 6:00:00 PM

***Location:*** UAB Hilton

***Planners/Content Reviewers/Speakers – Disclosures:***

Planners, Content Reviewers and Speaker have the following financial relationship(s) with commercial interests to disclose:

Christine N Stoops, DO : Nothing to disclose - 11/29/2023

Kara C Short, CRNP : Consulting Fee-Nuwellis|Royalties or Patent Beneficiary-International patent of intellectual property through UAB - 11/29/2023

Tennille N Webb, MD : Nothing to disclose - 10/30/2023

Stuart L. Goldstein, MD : Other: Consultant, Grant Funding-Medtronic, Inc.|Other: Consultant, Grant Funding-Nuwellis|Other: Consultant, Grand Funding, Speaker's Bureau-Baxter Healthcare|Other: Consultant, Grant Funding-BioPorto Diagnostics - 02/28/2024

Shina Menon, MD : Other: Use of Aquadex device-Nuwellis, Inc.|Other: Use of Carpediem-Medtronic - 10/22/2023

Colm Travers, MD : Grant or research support-Owlet Baby Care Inc. - 10/24/2023

Namasivayam Ambalavanan, MD : Consulting Fee-Shire LLC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-ResBiotic and AlveolusBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-ResBiotic and AlveolusBio|Consulting Fee-Radiometer (Relationship has ended) - 10/19/2023

Wally Carlo, MD : Nothing to disclose - 12/09/2023

David Askenazi, MD : Other: Consultant and Grant related to Plasmapheresis, CRRT-Baxter|Other: Consultant and Grant related to Aquapheresis, CRRT, Neonatal AKI-Nuwellis|Other: Consultant related to Nutrition in Children with Kidney Disease-Abbott Nutrition|Other: Consultant related to SCD-Seastar Medical|Other: Consultant related to Biomarkers-BioPorto|Grant or research support-Portero (Relationship has ended)|Grant or research support-Nuwellis|Grant or research support-Mozarc|Grant or research support-Leadiant (Relationship has ended)|Executive-Zorro-Flow - 02/15/2024

David Selewski, MD : Consulting Fee-Bioporto|Consulting Fee-Pharmacosmos|Consulting Fee-Travere Therapeutics (Relationship has ended) - 11/29/2023

Michelle C. Starr, MD : Nothing to disclose - 10/22/2023

Jennifer Charlton, MD : Nothing to disclose - 01/18/2024

Katja Gist, MD : Consulting Fee-Bioporto Diagnostics |Consulting Fee-Potrero Medical Inc|Grant or research support-Gerber Foundation - 10/19/2023

Ronnie Guillet, MD : Stocks or stock options, excluding diversified mutual funds-Zorro-Flow - 10/19/2023

Matthew Harer, MD : Nothing to disclose - 10/19/2023

Jennifer Jetton, MD : Nothing to disclose - 11/12/2023

Matka Marlais, MD : Nothing to disclose - 10/19/2023

Kimberly Reidy, MD : Grant or research support-Travere Therapeutics - 11/30/2023

Keia Sanderson, MD : Nothing to disclose - 01/09/2024

Meredith Schuh, MD : Nothing to disclose - 10/21/2023

Cara Slagle, MD : Consulting Fee-Medtronic|Paid consultant-Bioporto|Honoraria-AKI Critical Care Foundation|Consulting Fee-AM Pharma|Honoraria-UAB (Relationship has ended) - 05/23/2024

Enrico Vidal, MD : Nothing to disclose - 11/02/2023

***Designation/Accreditation:***

Children's of Alabama designates this Live Activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Children’s of Alabama is accredited by the Medical Association of the State of Alabama to provide continuing medical education for physicians.